A Mediterranean dietary pattern intervention does not improve cardiometabolic risk but does improve quality of life and body composition in an Aotearoa New Zealand population at increased cardiometabolic risk: A randomised controlled trial

Jeremy D. Krebs,Amber Parry‐Strong,Andrea Braakhuis,Anna Worthington,Troy L. Merry,Richard B. Gearry,Meika Foster,Mark Weatherall,Cheryl Davies,Jane Mullaney,Cecilia Ross,Denise Conroy,Anna Rolleston,Fiona E. Lithander
DOI: https://doi.org/10.1111/dom.16030
2024-10-31
Diabetes Obesity and Metabolism
Abstract:Aims To test if a New Zealand food–based Mediterranean diet (NZMedDiet) with behavioural intervention improves cardiometabolic health and wellbeing. Methods A randomised controlled trial comparing 12 weeks of the NZMedDiet to usual diet in participants with increased cardiometabolic risk (metabolic syndrome severity score [MetSSS] > 0.35). The intervention group was provided with food and recipes to meet 75% of their energy requirements, supported by a behavioural intervention to improve adherence. The primary outcome measure was (MetSSS) after 12 weeks. Results Two hundred individuals with mean (SD) age 49.9 (10.9) years of which 62% women were enrolled with their household/whānau. After 12 weeks, the mean (SD) MetSSS was 1.0 (0.7) in the control (n = 98) and 0.8 (0.5) in the intervention (n = 102) group; estimated difference (95% confidence interval [CI]) of −0.05 (−0.16 to 0.06), p = 0.35. The Mediterranean diet score (PyrMDS) was greater in the intervention group 1.6 (1.1–2.1), p
endocrinology & metabolism
What problem does this paper attempt to address?